Ryan Gonzales, MD
Hematology & Oncology · Fort Wayne, INNPI 1134330061
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.5%), food and beverage and other — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 18.8%. 2025 is the largest year on record at $11,152, 4.0 times the $2,762 reported in 2019.
Across 699 payments — averaging $54.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$7K
- Novartis$3K
- AstraZeneca$3K
- Karyopharm Therapeutics Inc.$3K
- Beigene USA, Inc.$2K
- Incyte Corporation$2K
- plus $18K from 54 others
What the payments were for
- Consulting fees$16,48943%
- Speaking & faculty fees$1,0003%
- Travel & lodging$6362%
- Food & beverage$16,08142%
- Education$1,1313%
- Other$2,5987%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,935 in reported general payments places this provider in the 85th percentile of 224 hematology & oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 35 | $682,435 |
| PomalystPomalidomide | 19 | $424,604 |
| CalquenceAcalabrutinib Maleate | 24 | $336,030 |
| BrukinsaZanubrutinib | 20 | $295,571 |
| XtandiEnzalutamide | 13 | $179,080 |
| EliquisApixaban | 98 | $91,756 |
| XareltoRivaroxaban | 84 | $74,742 |
| Abiraterone Acetate | 28 | $74,741 |
| VeozahFezolinetant | 12 | $6,800 |
| Letrozole | 105 | $3,227 |
| Hydroxyurea | 21 | $1,282 |
| Dexamethasone | 50 | $1,152 |
| Prochlorperazine Maleate | 25 | $408 |
| Gabapentin | 39 | $401 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 30 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,013 | $682,43535 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,534 | $424,60419 claims |
| AstraZenecaCalquence | $3,156 | $336,03024 claims |
| Beigene USA, Inc.Brukinsa | $2,114 | $295,57120 claims |
| Astellas Pharma US IncXtandi, Veozah | $301 | $185,88025 claims |
| PfizerEliquis | $319 | $91,75698 claims |
| Johnson & JohnsonXarelto | $1,210 | $74,74284 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $26 | $33726 claims |
| Lilly USA, LLCOlanzapine | $76 | $6711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Fort Wayne
- Ahad SadiqFort Wayne$430K
- Zhentao ZhangFort Wayne$167K
- Sreenivasa NattamFort Wayne$120K
- Praveen KolliparaFort Wayne$88K
- Dolly Quispe LeveauFort Wayne$74K
- Matthew CarrFort Wayne$51K
- Shalini ChitneniFort Wayne$46K
- Robert MangesFort Wayne$31K
- Michael TooleFort Wayne$27K
- Melanie ClarkFort Wayne$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.